US, European Covid vaccine developers make pledge to uphold testing rigour | The Business Standard
Skip to main content
  • Latest
  • Epaper
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Tuesday
June 17, 2025

Sign In
Subscribe
  • Latest
  • Epaper
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
TUESDAY, JUNE 17, 2025
US, European Covid vaccine developers make pledge to uphold testing rigour

Coronavirus chronicle

Reuters
08 September, 2020, 04:35 pm
Last modified: 08 September, 2020, 04:40 pm

Related News

  • US issues 'do not travel' alert for Israel
  • Lost angels: How the West is turning against the very immigrants who helped build it
  • Marines prepare for Los Angeles deployment as protests spread across US
  • Deal to get US-China trade truce back on track is done, Trump says
  • China's mega-embassy faces its MAGA nemesis

US, European Covid vaccine developers make pledge to uphold testing rigour

The companies, including Pfizer, GlaxoSmithKline and AstraZeneca, in a joint statement made a "historic pledge... to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first Covid-19 vaccines"

Reuters
08 September, 2020, 04:35 pm
Last modified: 08 September, 2020, 04:40 pm
File Photo: Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo
File Photo: Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo

Nine leading US and European vaccine developers pledged on Tuesday to uphold the scientific standards that their experimental immunisations will be held against, amid a hurried global race to contain the pandemic.

The companies, including Pfizer, GlaxoSmithKline and AstraZeneca, in a joint statement made a "historic pledge... to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first Covid-19 vaccines".

The unusual move to promise to play by well-established rules underlines a highly politicised debate over what action is needed to quickly rein in the spread of the deadly disease and to jumpstart global business and trade.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The head of the US Food and Drug Administration (FDA) said last month that the normal approval process may be bypassed for a Covid-19 vaccine as long as officials were convinced the benefits outweigh the risks, prompting a call for caution from the World Health Organisation.

Developers globally have yet to produce large-scale trial data showing actual infections in participants, yet Russia granted approval to a Covid-19 vaccine last month, prompting some Western experts to criticize a lack of testing.

The head of China's Sinovac Biotech said most of its employees and their families have already taken an experimental vaccine developed by the Chinese firm under the country's emergency-use programme.

"We want it to be known that also in the current situation we are not willing to compromise safety and efficacy," said co-signatory Ugur Sahin, the chief executive of Pfizer's German partner BioNTech.

"Apart from the pressure and the hope for a vaccine to be available as fast as possible, there is also a lot of uncertainty among people that some development steps may be omitted here," he added.

BioNTech and Pfizer have raised the prospect of unveiling pivotal trial data in October, potentially placing it at the centre of bitter US presidential politics ahead of the Nov. 3 election.

According to the statement, the nine companies pledge to follow established guidance from expert regulatory authorities such as the FDA.

Among other hurdles, approval must be based on large, diverse clinical trials with comparative groups that do not receive the vaccine in question. Participants and those working on the trial must not know which group they belong to, according to the pledge.

BioNTech's Sahin added there must be statistical certainty of 95 percent, in some cases higher, that a positive reading on efficacy does not just come from random variations but reflects the underlying workings of the compound.

The list of co-signatories is completed by Johnson & Johnson , Merck & Co, Moderna, Novavax and Sanofi.

Sahin said inclusion in the pledge broadly reflected a significant vaccines market share or a leading position in coronavirus vaccine development.

The frenetic development race has intensified safety concerns about an inoculation, polls have shown.

Western regulators have stressed they would not cut corners but rather prioritise the review workload and allow for development steps in parallel that would normally be handled consecutively.

covid-19 vaccine / US / Europe / Pfizer / AstraZeneca Covid-19 Vaccine / GlaxoSmithKline

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Israeli Prime Minister Benjamin Netanyahu attends a joint press conference with US Secretary of State Marco Rubio at the Prime Minister's office in Jerusalem, February 16, 2025. Photo: Ohad Zwigenberg/Pool via REUTERS/File Photo
    Killing Khamenei will end conflict: Netanyahu
  • Rising default loans threaten jobs, growth, trade
    Rising default loans threaten jobs, growth, trade
  • Bangladesh gains bigger share in US apparel market as China loses ground, sees 29% export growth in Jan-Apr
    Bangladesh gains bigger share in US apparel market as China loses ground, sees 29% export growth in Jan-Apr

MOST VIEWED

  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    Merger of 5 Islamic banks at final stage: BB governor
  • UCB launches Bangladesh's first microservices-based open API banking platform
    UCB launches Bangladesh's first microservices-based open API banking platform
  • Photo: Collected
    Pakistan rejects reports of missile supply to Iran
  • Infographic: TBS
    Non-performing loans surge by Tk74,570cr in Q1 as hidden rot exposed
  • BSEC seeks roadmap from 60 firms on Tk30cr capital compliance
    BSEC seeks roadmap from 60 firms on Tk30cr capital compliance
  • Former Bangladesh High Commissioner to the UK Saida Muna Tasneem. Photo: Collected
    ACC launches inquiry against ex-Bangladesh envoy Saida Muna, husband over laundering Tk2,000cr

Related News

  • US issues 'do not travel' alert for Israel
  • Lost angels: How the West is turning against the very immigrants who helped build it
  • Marines prepare for Los Angeles deployment as protests spread across US
  • Deal to get US-China trade truce back on track is done, Trump says
  • China's mega-embassy faces its MAGA nemesis

Features

The GLS600 overall has a curvaceous nature, with seamless blends across every panel. PHOTO: Arfin Kazi

Mercedes Maybach GLS600: Definitive Luxury

16h | Wheels
Renowned authors Imdadul Haque Milon, Mohit Kamal, and poet–children’s writer Rashed Rouf seen at Current Book Centre, alongside the store's proprietor, Shahin. Photo: Collected

From ‘Screen and Culture’ to ‘Current Book House’: Chattogram’s oldest surviving bookstore

1d | Panorama
Photos: Collected

Kurtis that make a great office wear

3d | Mode
Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

5d | Panorama

More Videos from TBS

Phulbari, Banglabandha Borders Closed Due to Protests by Indian Truck Workers

Phulbari, Banglabandha Borders Closed Due to Protests by Indian Truck Workers

4h | TBS World
Why is China's economy not booming?

Why is China's economy not booming?

5h | Others
An additional 36 countries may be added to the travel restrictions imposed by the United States.

An additional 36 countries may be added to the travel restrictions imposed by the United States.

8h | TBS World
NPLs surge by Tk74,570cr in Q1 as hidden rot exposed

NPLs surge by Tk74,570cr in Q1 as hidden rot exposed

8h | TBS Insight
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net